Introduction to the CFHT Legacy Survey final release (CFHTLS T0007)

The Canada-France-Hawaii Telescope Legacy Survey (CFHTLS) is a high impact scientific program which will see its final official release open to the world in 2012. That release will seal the legacy aspect of the survey which has already produced a large collection of scientific articles with topics ranging from cosmology to the Solar system. The survey core science was focused on dark energy and dark matter: the full realization of the scientific potential of the data set gathered between 2003 and 2009 with the MegaCam wide-field imager mounted at the CFHT prime focus is almost complete with the Supernovae Legacy Survey (SNLS) team preparing its third and last release (SNLS5), and the CFHTLenS team planning the release based around the cosmic shear survey later this year. While the data processing center TERAPIX offered to the CFHTLS scientific community regular releases over the course of the survey in its data acquisition phase (T0001-T0006), the final release took three years to refine in order to produce a pristine data collection photometrically calibrated at better than the percent both internally and externally over the total survey surface of 155 square degrees in all five photometric bands (u*, g', r', i', z'). This final release, called T0007, benefits from the various advances in photometric calibration MegaCam has benefited through the joint effort between SNLS and CFHT to calibrate MegaCam at levels unexplored for an optical wide-field imager. T0007 stacks and catalogs produced by TERAPIX will be made available to the world at CADC while the CDS will offer a full integration of the release in its VO tools from VizieR to Aladin. The photometric redshifts have been produced to be released in phase with the survey. This proceeding is a general introduction to the survey and aims at presenting its final release in broad terms.Peer reviewed: YesNRC publication: Ye

Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity

Whereas cancers grow within host tissues and evade host immunity through immune-editing and immunosuppression, tumours are rarely transmissible between individuals. Much like transplanted allogeneic organs, allogeneic tumours are reliably rejected by host T cells, even when the tumour and host share the same major histocompatibility complex alleles, the most potent determinants of transplant rejection. How such tumour-eradicating immunity is initiated remains unknown, although elucidating this process could provide the basis for inducing similar responses against naturally arising tumours. Here we find that allogeneic tumour rejection is initiated in mice by naturally occurring tumour-binding IgG antibodies, which enable dendritic cells (DCs) to internalize tumour antigens and subsequently activate tumour-reactive T cells. We exploited this mechanism to treat autologous and autochthonous tumours successfully. Either systemic administration of DCs loaded with allogeneic-IgG-coated tumour cells or intratumoral injection of allogeneic IgG in combination with DC stimuli induced potent T-cell-mediated antitumour immune responses, resulting in tumour eradication in mouse models of melanoma, pancreas, lung and breast cancer. Moreover, this strategy led to eradication of distant tumours and metastases, as well as the injected primary tumours. To assess the clinical relevance of these findings, we studied antibodies and cells from patients with lung cancer. T cells from these patients responded vigorously to autologous tumour antigens after culture with allogeneic-IgG-loaded DCs, recapitulating our findings in mice. These results reveal that tumour-binding allogeneic IgG can induce powerful antitumour immunity that can be exploited for cancer immunotherapy